Labeled for this condition
Medicines for enlarged prostate (bph)
8 medicines have an FDA label indicated for enlarged prostate (bph); 8 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for enlarged prostate (bph)?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Tadalafil | Cialis, Tadliq, Adcirca | 49 labelers | $0.167 per tablet 20 mg tablet | No | No current entry | 12 |
| Doxazosin | Cardura | 29 labelers | $0.0752 per tablet 1 mg tablet | No | No current entry | 11 |
| Terazosin | Tezruly | 21 labelers | $0.106 per capsule 2 mg capsule | No | No current entry | 2 |
| Finasteride | Proscar, Propecia | 30 labelers | $0.0688 per tablet 5 mg tablet | No | No current entry | 6 |
| Tamsulosin | none listed | 38 labelers | $0.05 per capsule 0.4 mg capsule | No | No current entry | 3 |
| Silodosin | none listed | 13 labelers | $0.319 per capsule 8 mg capsule | No | No current entry | 1 |
| Dutasteride | none listed | 13 labelers | $0.157 per capsule 0.5 mg capsule | No | No current entry | 0 |
| Alfuzosin | Uroxatral | 10 labelers | $0.105 per tablet 10 mg tablet | No | No current entry | 1 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price